Clinical study on biapenem in respiratory tract infections

Abstract

The clinical efficacy and safety of biapenem (BIPM) were evaluated in 9 patients with respiratory tract infections.
The clinical efficacy was evaluated to be good in 8 patients, poor in 1, showing an 88.9% efficacy rate. Bacteriological efficacy was determined to be eradicated in 3 strains, decreased in 1. Diarrhea occurred in one patient as a side effect. Abnormal laboratory findings (elevation of transaminase, LDH) were observed in 2 patients, however these changes posed no clinical problems.